The study objective was to target the aldose reductase enzyme in order to alleviate oxidative stress and the manifestations of hyperglycemia that eventually lead to the physical disabilities associated with diabetic neuropathy. This evidence concerns the gene AKR1B1 and diabetic neuropathy.